Chromosome 17 deletion clinical trials

The registry lists 23 studies for Chromosome 17 deletion across more than 10 countries. 2 are recruiting or about to start. 5 of them are mainly about Chromosome 17 deletion (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Chromosome 17 deletion studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 16
Recruiting: 2
Active, not recruiting: 2
Status unknown: 1
Withdrawn: 1
Terminated: 1

Phase

Phase 2: 12
Phase 3: 4
Phase 1: 3
Early Phase 1: 1

Where

United States: 13
France: 5
Germany: 4
Australia: 3
Canada: 3
United Kingdom: 3

Who runs them

AbbVie (6) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (1) · Fatih Demirkan, MD (1) · Acerta Pharma BV (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Memgen, LLC (1) · Institute of Hematology & Blood Diseases Hospital, China (1)

What is being tested here

Drugs under test in Chromosome 17 deletion studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Rocbrutinib	1	1	1
Venetoclax	0	3	6
Fludarabine	0	0	5
Fludarabine phosphate	0	0	3
Pomalidomide	0	0	2
Ibrutinib	0	0	2
Mycophenolic Acid	0	0	2
Melphalan	0	0	2
Daratumumab	0	0	1
Dexamethasone	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Antimetabolites 5

Coming up

1phase 3 study under way

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Jul 2027A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients · Fondazione EMN Italy Onlus

Who these studies take

Of the 2 Chromosome 17 deletion studies recruiting now, 2 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 2
Age	Women	Men
10	0 (0%)	0 (0%)
18	2 (100%)	2 (100%)
30	2 (100%)	2 (100%)
40	2 (100%)	2 (100%)
50	2 (100%)	2 (100%)
65	2 (100%)	2 (100%)
75	2 (100%)	2 (100%)
85	2 (100%)	2 (100%)

Across all 23 studies, recruiting or not: 17% stop at 75 or younger and 4% at 65; 9% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. search them.